Nuvation Bio Inc
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug c… Read more
Market Cap & Net Worth: Nuvation Bio Inc (NUVB)
Nuvation Bio Inc (NYSE:NUVB) has a market capitalization of $1.46 Billion ($1.46 Billion) as of March 19, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #7360 globally and #3921 in its home market, demonstrating a -8.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nuvation Bio Inc's stock price $4.28 by its total outstanding shares 341833433 (341.83 Million).
Nuvation Bio Inc Market Cap History: 2020 to 2026
Nuvation Bio Inc's market capitalization history from 2020 to 2026. Data shows change from $4.00 Billion to $1.46 Billion (-14.14% CAGR).
Nuvation Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nuvation Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
115.49x
Nuvation Bio Inc's market cap is 115.49 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $909.28 Million | $7.87 Million | -$567.94 Million | 115.49x | N/A |
Competitor Companies of NUVB by Market Capitalization
Companies near Nuvation Bio Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Nuvation Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Nuvation Bio Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Nuvation Bio Inc's market cap moved from $4.00 Billion to $ 1.46 Billion, with a yearly change of -14.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.46 Billion | -52.23% |
| 2025 | $3.06 Billion | +236.84% |
| 2024 | $909.28 Million | +76.16% |
| 2023 | $516.17 Million | -21.35% |
| 2022 | $656.32 Million | -77.41% |
| 2021 | $2.91 Billion | -27.35% |
| 2020 | $4.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Nuvation Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.46 Billion USD |
| MoneyControl | $1.46 Billion USD |
| MarketWatch | $1.46 Billion USD |
| marketcap.company | $1.46 Billion USD |
| Reuters | $1.46 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.